Acquired by Shockwave Medical, Inc. in Apr 2023
NVCN - Neovasc Inc.
TSX
->
Healthcare
->
Medical Devices
Richmond,
Canada
Type: Equity
NVCN price evolution
NVCN
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 1 May 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.79 | $31.25 | $37.63 | $44.16 |
| Short term investments | ||||
| Net receivables | $2.5 | $1.69 | $1.64 | $1.41 |
| Inventory | $1.09 | $1.29 | $1.27 | $1.4 |
| Total current assets | $29.78 | $34.6 | $40.9 | $47.95 |
| Long term investments | ||||
| Property, plant & equipment | $0.5 | $0.51 | $0.5 | $0.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $38.73 | $44.58 | $51.93 | $60.05 |
| Current liabilities | ||||
| Accounts payable | $2.18 | $0.79 | $1.49 | $1.13 |
| Deferred revenue | ||||
| Short long term debt | $0.22 | $0.36 | $0.21 | $0.25 |
| Total current liabilities | $10.07 | $4.1 | $4.23 | $3.72 |
| Long term debt | $12.78 | $12.23 | $11.97 | $12.24 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $22.89 | $16.51 | $16.36 | $16.28 |
| Shareholders' equity | ||||
| Retained earnings | -$463.19 | -$449.35 | -$441.13 | -$432.15 |
| Other shareholder equity | -$6.23 | -$6.23 | -$6.23 | -$6.23 |
| Total shareholder equity | $15.84 | $28.06 | $35.57 | $43.77 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.79 | $51.54 | $12.94 | $5.29 |
| Short term investments | ||||
| Net receivables | $2.5 | $1.41 | $1.08 | $0.8 |
| Inventory | $1.09 | $1.48 | $0.84 | $0.62 |
| Total current assets | $29.78 | $55.22 | $15.73 | $8.02 |
| Long term investments | ||||
| Property, plant & equipment | $0.5 | $0.64 | $1.63 | $1.49 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.15 | $2.09 | ||
| Total investments | ||||
| Total assets | $38.73 | $66.22 | $17.88 | $10.11 |
| Current liabilities | ||||
| Accounts payable | $2.18 | $1.43 | $3.71 | $3.99 |
| Deferred revenue | ||||
| Short long term debt | $0.22 | $0.35 | $0.42 | $6.93 |
| Total current liabilities | $10.07 | $4.98 | $7.66 | $14.72 |
| Long term debt | $12.78 | $8.61 | $8.24 | $8.64 |
| Total noncurrent liabilities | $8.24 | $9.83 | ||
| Total debt | ||||
| Total liabilities | $22.89 | $14 | $15.9 | $24.55 |
| Shareholders' equity | ||||
| Retained earnings | -$463.19 | -$420.12 | -$395.23 | -$366.53 |
| Other shareholder equity | -$6.23 | -$7.89 | -$7.62 | -$6.14 |
| Total shareholder equity | $15.84 | $52.23 | $1.98 | -$14.45 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 1 May 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.45 | $0.92 | $0.82 | |
| Cost of revenue | $1.29 | $1.25 | $1.18 | |
| Gross Profit | $0.16 | -$0.33 | -$0.36 | |
| Operating activities | ||||
| Research & development | $5.89 | $4.04 | $4.34 | |
| Selling, general & administrative | $7.65 | $3.25 | $4.5 | |
| Total operating expenses | $14.83 | $8.54 | $10.02 | |
| Operating income | -$13.38 | -$7.62 | -$9.2 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.03 | |||
| Interest expense | -$0.35 | -$0.43 | -$0.39 | |
| Net income | ||||
| Net income | -$13.84 | -$8.23 | -$8.98 | |
| Income (for common shares) | -$13.84 | -$8.23 | -$8.98 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.81 | $2.55 | $1.96 | $2.09 |
| Cost of revenue | $5.07 | $0.56 | $0.45 | $0.46 |
| Gross Profit | -$1.27 | $1.99 | $1.51 | $1.63 |
| Operating activities | ||||
| Research & development | $17.54 | $15.09 | $19.91 | $19.56 |
| Selling, general & administrative | $19.05 | $15.56 | $15.4 | $10.68 |
| Total operating expenses | $41.67 | $33.66 | $37.13 | $32.24 |
| Operating income | -$37.86 | -$31.11 | -$35.17 | -$30.15 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.03 | $0.09 | -$0.52 | $0.03 |
| Interest expense | -$1.52 | |||
| Net income | ||||
| Net income | -$41.2 | -$24.89 | -$28.7 | -$35.13 |
| Income (for common shares) | -$41.2 | -$24.89 | -$28.7 | -$35.13 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Net income | -$13.84 | -$8.23 | -$8.98 | -$10.16 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.09 | $0.1 | $0.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$5.39 | -$6.3 | -$6.26 | -$6.98 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.05 | ||
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.05 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | $0 | ||
| Net borrowings | -$0.08 | -$0.08 | -$0.08 | -$0.1 |
| Total cash flows from financing | -$0.07 | -$0.07 | -$0.22 | -$0.39 |
| Effect of exchange rate | $0.06 | -$0.11 | -$0.02 | |
| Change in cash and equivalents | -$5.46 | -$6.38 | -$6.53 | -$7.37 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$41.2 | -$24.89 | -$28.7 | -$35.13 |
| Operating activities | ||||
| Depreciation | $0.3 | $0.67 | $0.77 | $0.64 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$24.93 | -$27.11 | -$29.44 | -$23.97 |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0.16 | -$0.34 | -$0.24 |
| Investments | ||||
| Total cash flows from investing | -$0.05 | -$0.16 | -$0.35 | -$0.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $66.4 | $45.37 | $20.8 |
| Net borrowings | -$0.34 | -$0.49 | -$8.32 | -$0.51 |
| Total cash flows from financing | -$0.76 | $65.88 | $37.43 | $20.29 |
| Effect of exchange rate | -$0.06 | |||
| Change in cash and equivalents | -$25.75 | $38.6 | $7.64 | -$3.95 |
News
|
Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last year
Simply Wall St. via Yahoo Finance
9 Mar 2023
|
|
Neovasc (TSE:NVC) Rating Lowered to Neutral at HC Wainwright
ETF DAILY NEWS
20 Jan 2023
|
|
The Funded: Shell plans to buy struggling Bay Area EV charging business Volta
American City Business Journals
18 Jan 2023
|
|
Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome
Zacks via Yahoo Finance
18 Jan 2023
|
|
3 Medical Instruments Stocks on Recovery Path After Dismal 2022
Zacks via Yahoo Finance
21 Dec 2022
|
|
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance
10 Nov 2022
|
|
Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance
12 May 2022
|
|
LENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
9 May 2022
|
|
74 Biggest Movers From Yesterday
Benzinga
29 Apr 2022
|
|
Hologic (HOLX) Q2 Earnings and Revenues Surpass Estimates
Zacks via Yahoo Finance
27 Apr 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.75M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 90.79% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 8.02 |
| Cash/Share | 9.37 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.45 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.96 |
| Quick ratio | 2.85 |